Biotech firms will continue to receive funding, but pricing will always be a pressing concern as firms balance profit and loss.
The lengthy process of developing and gaining approval for biotech solutions hurts bottom line profits, with 98% of biotech executives reporting revenue loss from regulatory changes. Biotech firms will continue to receive funding, but pricing will always be a pressing concern as firms balance profit and loss.